Lyell Immunopharma (LYEL) Operating Income: 2020-2025
Historic Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -$37.3 million.
- Lyell Immunopharma's Operating Income rose 26.24% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$342.9 million, marking a year-over-year decrease of 57.94%. This contributed to the annual value of -$358.8 million for FY2024, which is 45.24% down from last year.
- Latest data reveals that Lyell Immunopharma reported Operating Income of -$37.3 million as of Q3 2025, which was up 20.97% from -$47.1 million recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Operating Income ranged from a high of -$14.8 million in Q4 2022 and a low of -$201.1 million during Q4 2024.
- Over the past 3 years, Lyell Immunopharma's median Operating Income value was -$57.4 million (recorded in 2025), while the average stood at -$68.0 million.
- Per our database at Business Quant, Lyell Immunopharma's Operating Income skyrocketed by 68.90% in 2022 and then tumbled by 302.52% in 2023.
- Quarterly analysis of 5 years shows Lyell Immunopharma's Operating Income stood at -$47.5 million in 2021, then spiked by 68.90% to -$14.8 million in 2022, then tumbled by 302.52% to -$59.5 million in 2023, then crashed by 238.02% to -$201.1 million in 2024, then increased by 26.24% to -$37.3 million in 2025.
- Its Operating Income was -$37.3 million in Q3 2025, compared to -$47.1 million in Q2 2025 and -$57.4 million in Q1 2025.